Cowen initiated coverage on shares of Magenta Therapeutics (NASDAQ:MGTA) in a report released on Monday morning, MarketBeat reports. The brokerage issued an outperform rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Wedbush assumed coverage on shares of Magenta Therapeutics in a research note on Monday. They issued an outperform rating and a $22.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of Magenta Therapeutics in a research report on Monday. They issued an overweight rating and a $18.00 target price on the stock. Finally, Goldman Sachs Group assumed coverage on shares of Magenta Therapeutics in a research report on Monday. They issued a buy rating and a $18.00 target price on the stock.

Shares of Magenta Therapeutics opened at $14.01 on Monday, according to MarketBeat. Magenta Therapeutics has a 12-month low of $11.45 and a 12-month high of $16.33.

In other news, Director David Scadden bought 6,600 shares of the company’s stock in a transaction dated Monday, June 25th. The shares were acquired at an average cost of $15.00 per share, with a total value of $99,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Featured Story: Short Selling

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.